Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Font Size

New Warnings on Humira Drug Label

Maker Says 'Rare' Problems Seen With Rheumatoid Arthritis Drug
WebMD Health News

Nov. 9, 2004 -- The rheumatoid arthritis drug Humira has new additions on its warning label, according to a letter from the drug's maker, Abbott Laboratories Inc.

Humira was approved by the FDA in 2002. It's administered by injection and works by blocking an inflammation-causing protein called tumor necrosis factor alpha, or TNF-alpha. About 75,000 people worldwide have taken Humira since 2003, according to news reports.

Abbott's letter mentions rare cases of hypersensitivity reactions, blood cell deficiencies, and problems from taking Humira with another rheumatoid arthritis drug, Kineret.

The letter also says "serious infections" were seen in clinical trials when Humira was taken with Kineret, which is made by Amgen.

"The combination of Humira and [Kineret] is not recommended," says the letter, dated Nov. 5, which was sent to health care professionals and is posted on the FDA web site.

Other problems include "rare" cases of anaphylaxis, which is a sudden, life-threatening allergic reaction. The new warning says Humira should be "discontinued immediately" if anaphylactic or other serious reactions occur, noting that overall, about 1% of patients taking Humira in clinical trials had allergic reactions.

The new label also warns about "infrequent" and "rare" reports of blood cell deficiencies including aplastic anemia. Aplastic anemia occurs when the bone marrow stops making enough blood cells.

Patients taking Humira should "seek immediate medical attention" if they develop persistent fever, bruising, bleeding, or pallor, says the letter.

Humira isn't the only rheumatoid arthritis drug in its class with warnings on its label. Competitor drugs Enbrel and Remicade have labels that address possible rare blood problems, and all three drugs -- Humira, Enbrel, and Remicade -- note the risk of tuberculosis.

Apparently, the label change was made this summer. Abbott's revised Humira label, posted on the FDA's web site, is dated July 2004.

According to news reports, an Abbott spokesperson said the company recently sent the letter to let health care providers know that the language was "consistent" with warnings from similar drugs.

Today on WebMD

rubbing hands
Avoid these 6 common mistakes.
mature couple exercising
Decrease pain, increase energy.
mature woman threading needle
How much do you know?
Swelling, fatigue, pain, and more.
Lucille Ball
Hand bones X-ray
prescription pills
Woman massaging her neck
woman roasting vegetables in oven
Woman rubbing shoulder
Working out with light weights